
Dyne Therapeutics (DYN) Stock Forecast & Price Target
Dyne Therapeutics (DYN) Analyst Ratings
Bulls say
Dyne Therapeutics is a clinical-stage neuromuscular disease company with a promising drug platform and a strong pipeline of potential treatments. However, the company faces significant risks in terms of protecting its intellectual property and competing against larger, more established companies in the gene therapy/oligonucleotide medicines space. With a cash balance expected to provide operational runway into 2028, Dyne's potential to become a leader in the market is high, but regulatory and clinical risks must be carefully managed. An NPV analysis projects a 12-month price target of $38 per share by considering future revenue from commercial sales and applying probabilities of success to the company's various pipeline assets.
Bears say
Dyne Therapeutics is a clinical-stage neuromuscular disease company focused on discovering and advancing therapeutics for genetically driven diseases. However, despite their innovative FORCE platform and potential treatments for serious conditions like DM1, DMD, and FSHD, the Company is facing major competition in the biotech and pharmaceutical industries, which possess greater resources, experience and could render their products obsolete. Additionally, Dyne is a development stage company that currently has no revenue, meaning they are reliant on external financing, which could be difficult to obtain. As a financial analyst, it is necessary to consider these factors in a negative outlook for Dyne's stock.
This aggregate rating is based on analysts' research of Dyne Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Dyne Therapeutics (DYN) Analyst Forecast & Price Prediction
Start investing in Dyne Therapeutics (DYN)
Order type
Buy in
Order amount
Est. shares
0 shares